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Abstract 
Atherosclerosis is primarily a disease of lipid metabolism and inflammation, however, it is also 
closely associated with endothelial extracellular matrix (ECM) remodeling, with fibronectin 
accumulating in the laminin-collagen basement membrane. To investigate how fibronectin 
modulates inflammation in arteries, we replaced the cytoplasmic tail of the fibronectin receptor 
integrin D5 with that of the collagen/laminin receptor integrin D2. This chimera suppressed 
inflammatory signaling in endothelial cells on fibronectin and in knock-in mice. Fibronectin 
promoted inflammation by suppressing anti-inflammatory cAMP.  cAMP was activated through 
endothelial prostacyclin secretion, however, this was ECM-independent. Instead, cells on 
fibronectin suppressed cAMP via enhanced phosphodiesterase (PDE) activity, through direct 
binding of integrin D5 to phosphodiesterase-4D5 (PDE4D5), which induced PP2A-dependent 
dephosphorylation of PDE4D5 on the inhibitory site Ser561. In vivo knockdown of PDE4D5 
inhibited inflammation at athero-prone sites. These data elucidate a molecular mechanism 
linking ECM remodeling and inflammation, thereby identifying a new class of therapeutic targets.  
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Introduction 
Atherosclerosis is an inflammatory disease of large to mid-sized arteries that is strongly linked 
to lipid metabolism 1. Current concepts and clinical approaches focus mainly on these aspects. 
However, atherosclerotic plaques occur mainly in regions of arteries with disturbed flow 2, 3, 
which  triggers oxidative stress, activation of NF-NB and other mediators, endothelial 
inflammatory gene expression, and leukocytes recruitment 4.  These local influences synergize 
with systemic risk factors such as high plasma LDL-cholesterol and triglycerides, hypertension, 
diabetes or smoking, to induce atherosclerotic plaques 5.   
Inflammation and ECM remodeling are closely associated across many biological systems and 
disease processes 6-8.  Inflammation induces ECM remodeling, with increases in provisional 
ECM proteins such as fibronectin, osteopontin and fibrin.  Conversely, ECM proteins and 
fragments modulate inflammatory processes.  These complex interactions between ECM and 
inflammatory pathways contribute to normal developmental and adult remodeling, and to a 
variety of pathologies.    
In stable, unperturbed vessels, the subendothelial basement membrane consists mainly of 
collagen IV, laminin and associated proteoglycans with minimal fibronectin (FN) 9. By contrast, 
fibronectin expression and matrix assembly are upregulated during development, angiogenesis 
and flow-dependent vessel remodeling 10-12. FN is also deposited in the intima at atheroprone 
regions of arteries 13. This occurs even in athero-resistant WT mice, associated with endothelial 
inflammatory gene expression, indicating that it is an early event.  FN increases in 
hypercholesterolemic mice together with atherosclerotic plaque progression.  Studies in 
genetically modified mice support a causal role for FN in atherosclerosis 14-16.  
In vitro studies with endothelial cells (ECs) showed that disturbed flow or acute changes in flow 
activates inflammatory pathways such as NF-NB, and induces expression of leukocyte 
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recruitment molecules such as ICAM-1, MCP-1 and VCAM-117, 18. However, these events 
depend strongly on the ECM proteins to which the ECs adhere: cells on collagen I or IV, or 
basement membrane protein (matrigel) suppress NF-NB, JNK and PAK in response to flow and 
soluble inflammatory mediators but are activated in ECs on FN 13, 19-21. Selective activation of 
cAMP and protein kinase A (PKA) in cells on collagen or basement membrane protein relative 
to FN mediates the suppression of inflammatory pathways 22,23. But how different integrins 
control cAMP/PKA and inflammation is unknown.   
The major fibronectin receptor, D5E1, and the major collagen/laminin receptor, D2E1, that are 
strongly implicated in pro- vs. anti-inflammatory signaling in vitro and in vivo 24, 25 share the 
common E1 subunit. While D2E1 binds best to fibrillar collagens, it also serves as a functionally 
relevant receptor for collagen IV and laminins 26.  We therefore hypothesized that the 
cytoplasmic domains of the unique integrin alpha subunits may determine differential 
inflammatory signaling. In this study, we examined chimeric in which the cytoplasmic tail of 
integrin D5 was replaced by that of D2.  Our results show that ECM-dependent differential 
inflammatory signaling is due to an interaction of the D5 cytoplasmic domain with the cAMP-
specific phosphodiesterase PDE4D5, with consequent regulation of PDE4D5 phosphorylation, 
likely by protein phosphatase 2A (PP2A).  
Results 
An integrin D5/2 chimera blocks flow-dependent inflammatory signaling 
To examine ECM-specific signaling, we constructed a chimeric integrin in which the D5 
cytoplasmic tail was replaced with the D2 tail (Fig. 1a). When over-expressed in bovine aortic 
endothelial cells (BAECs) the integrin D5/2 chimera localized to the cell surface (Fig. S1a) and 
hetero-dimerized with the integrin E1 subunit similarly to wild type (Fig. S1b). Chimera-
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expressing BAECs adhered and spread normally on FN (Fig. S1c, Fig. 2d, e), and showed 
normal FAK activation, FN fibrillogenesis and alignment in laminar flow (Fig. S1d, e, f). We then 
investigated shear-dependent inflammatory responses. The critical inflammatory transcription 
factor NF-NB shows transient activation by onset of flow, and sustained activation by oscillatory 
flow 27, 28. In both cases, the D5/2 chimera blocked NFNB activation (Fig. 1b, c) and expression 
of the NFNB target gene ICAM-1 (Fig. 1d). We also noted that the D5/2 chimera gave somewhat 
higher basal activation of NF-NB and other inflammatory pathways, but this also occurs with 
normal ECs on collagen or basement membrane protein 13, 21.  While this feature has not been 
further investigated, the combined results demonstrate that the D5/2 chimera phenocopies cells 
on basement membranes. 
ECM also modulates endothelial responses to soluble inflammatory mediators 19, 24.  IL-1E and 
oxidized LDL are two critical inflammatory mediators in atherosclerosis that also activate NF-NB. 
IL-1E and oxidized LDL strongly activated NF-NB in control ECs on FN, whereas control cells on 
matrigel, or D5/2 chimera cells on FN were largely resistant (Fig. 1e-g). Previous results showed 
that selective activation of the cAMP/PKA pathway suppressed NF-NB on coll IV-laminin 
basement membranes 22. Shear stress activated PKA in cells expressing the D5/2 chimera but 
not WT D5 on FN (Fig. 1h).  Furthermore, blocking PKA with PKI 14-22 amide, a cell permeable 
PKA inhibitor, restored NF-NB activity in chimera-expressing cells (Fig. 1i).  Together, these 
data show that differential PKA activation and subsequent inflammatory responses are 
mediated by the integrin D tails.  
Integrin chimera knock-in mice  
To investigate the role of integrin D tails in vivo, we made knock-in mice in which the exon 
encoding the endogenous integrin D5 cytoplasmic domain was replaced with that of integrin D2 
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following Cre-mediated recombination (Fig. 2a). Breeding of D5/2-floxed-neo mice with CMV-
Cre TG mice resulted in replacement of WT integrin D5 with the D5/2 chimera (Fig. 2b, c).  
These mice were viable and able to reproduce. A complete analysis of these mice will be 
reported elsewhere; in this study, we focused on endothelial phenotype. To confirm functionality, 
ECs isolated from WT and knock-in mice were plated on FN.  The D5/2 cells showed no 
differences in adhesion or spreading (Fig. 2d, e), confirming normal function. Endothelial 
inflammatory activation marked by elevated expression of fibronectin, ICAM-1 and VCAM-1 
occurs in regions of disturbed flow in wild type C57Bl6 mice 13 and is a strong marker for 
susceptibility to atherosclerosis 29, 30.  Staining for these proteins in the athero-prone inner 
curvature of the aortic arch was greatly reduced in integrin D5/2 knock-in mice (Fig. 2f). Thus, 
the integrin D5/2 chimera suppresses flow-dependent early inflammation in vivo.  
PGI2 mediates flow-dependent cAMP-PKA activation 
We next addressed how the ECM-integrin interaction modulates flow-dependent cAMP-PKA 
activation. The pathway by which flow activates cAMP and PKA is unknown, however, flow can 
induce PGI2 (prostacyclin) secretion in ECs 31, which binds a Gs-coupled receptor to activate 
adenylate cyclase and induce cAMP production 32, which promotes vasodilation and inhibits 
thrombosis and inflammation 33.  To test this pathway, HUVECs on matrigel were subject to flow 
with or without the cyclooxygenase (COX) inhibitor aspirin to block PGI2 synthesis, or the PGI2 
receptor antagonist RO1138452 to block PGI2 signaling.  Both of these treatments efficiently 
inhibited shear stress-dependent PKA activation (Fig. 3a). They also conferred NFNB activation 
by flow in cells on matrigel (Fig. 3b, c), confirming the importance of PKA in suppressing 
inflammatory pathways. Similarly, in D5/2 chimera cells on FN, blocking prostacyclin synthesis 
(with indomethacin) or the PGI2 receptor inhibited flow-induced PKA activation (Fig. 3d) and 
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conferred NF-NB activation (Fig. 3e, f). Thus, suppression of NF-NB by adhesion of cells to 
basement membranes is mediated by prostacyclin and its receptor. 
Next, to test whether shear stress-dependent PGI2 secretion is ECM-specific, we analyzed the 
stable prostacyclin metabolite 6-keto-PGF1D, an approach that circumvents the instability of 
PGI2.  Flow greatly increased 6-keto-PGF1D production, consistent with published data 31, 34. 
However, 6-keto-3*)Į levels did not differ between FN and matrigel (Fig. 3g).  Thus, 
prostacyclin production cannot account for the difference in cAMP and PKA activation in cells on 
different matrices.  
PDE4D is required for ECM-specific NFNB activation 
We next considered whether differential cAMP degradation might mediate the observed ECM 
specificity. Phosphodiesterases (PDEs) are the enzymes that hydrolyze cAMP to reduce or 
terminate signaling 35, 36. We focused on the PDE4 family, which are abundant in endothelial 
cells 37-40. We reasoned that if PDE4 is critical, its inhibition should restore PKA activation in 
endothelial cells on FN to levels similar to those on collagen or basement membranes. We first 
tested the PDE4 inhibitor rolipram, which increased shear-dependent PKA activation in cells on 
FN (Fig. 4a) and abolished flow-dependent NFNB activation, without affecting NFNB activity on 
collagen (Fig. 4b). By contrast, flow-dependent AMPK activation was unaffected by ECM or 
rolipram (Fig. S2a).  PDE4 compartmentalization by protein-protein interactions mediates 
functional specificity in many systems 41. Among the PDE4 sub-families, both PDE4C and 
PDE4D were reported in endothelial cells 42. The PDE4D subfamily has eleven splicing variants, 
however, we used a panPDE4D antibody and a PDE4D5-specific antibody to show that 
PDE4D5 is the only isoform detected in HUVEC and BAEC cells (Fig. S2b).  
We next examined whether PDE4D5 associates with integrins. Immunoprecipitation of 
endogenous PDE4D5 from HUVECs with two different antibodies brought down D5 but not D2 
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integrin (Fig. 4c). Immunoprecipitating WT D5 or the D5/2 chimera showed that this interaction 
required the D5 cytoplasmic domain (Fig. 4d). To investigate PDE4D function in flow-dependent 
NFNB activation, we performed knock-down and reconstitution experiments. PDE4D knock-
down almost completely abolished shear stress-dependent NFNB activation in cells on FN, 
which was rescued by an siRNA-resistant construct (Fig. 4e). To test whether targeting PDE4D5 
to focal adhesion is sufficient for these effects, we fused the focal adhesion targeting domain of 
FAK to PDE4D5 43. This construct strongly localized to focal adhesions in cells on matrigel (Fig. 
S2c) and conferred flow-induced NFNB activation (Fig. 4f). This construct also reduced shear 
stress-dependent Creb phosphorylation, confirming suppression of PKA activity.   
Direct interaction between the PDE4D5 UCR2 linker and integrin D5  
We next mapped the integrin binding region in PDE4D5 using bacterially expressed and purified 
fragments of PDE4D5 (Fig. 5a) to pull down integrin D5 from cell lysates. Binding was observed 
only with the regulatory upstream conserved region 2 (UCR2) with flanking connecting 
segments (Fig. 5b). Using purified integrin D tail fusion proteins that form coiled coil domain-
mediated homo-dimers 44, only integrin D5 bound the purified PDE4D5 F2 fragment, indicating 
that the association is direct and specific (Fig. 5c). Examining a series of deletions (Fig. 5d) 
showed that the C-terminal 13 amino acids from GST-F1-F2 is required for the interaction (Fig. 
5e). Among those 13 amino acids, mutation of K292KKR295 to either EEEE or AAAA completely 
blocked, and single amino acid substitutions partially blocked the interaction (Fig. 5f). Thus, a 
short, basic sequence in the connecting segment between UCR2 and the catalytic domain is 
required for binding integrin D5. 
To further validate this interaction, cells expressing WT or mutated GFP-PDE4D5 were plated 
on fibronectin or collagen, then subject to flow for 15 min.  In cells on FN, WT PDE4D5 but not 
PDE4D5 with a mutated D5 binding sequence co-localized with the focal adhesion marker 
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vinculin; co-localization was also lost in cells on collagen (Fig. 5g).  Thus, the interaction with D5 
specifically recruits PDE4D5 to focal adhesions.  
 
Integrin D5 binding is required for NF-NB activation on fibronectin 
To address whether the interaction between integrin D5 and PDE4D5 is required for pro-
inflammatory signaling in cells on FN, we reconstitution PDE4D5 knock-down cells with WT or 
mutant PDE4D5.  Whereas the WT PDE4D5 construct recovered NFNB activation, 4E and 4A 
mutants were inactive, as was catalytically dead PDE4D5 (D556A) (Fig. 5h). Thus, PDE4D 
binding to integrinD5 and catalytic activity are required for inflammatory signaling. Together, 
these results show that recruitment of PDE4D5 to focal adhesions via D5 binding mediates its 
pro-inflammatory function by suppressing anti-inflammatory PKA activation. 
Regulation of PDE4D phosphorylation by integrin D5 
We then considered whether localization of PDE4D5 by integrin D5 is the sole determinant of 
these effects or whether PDE4 catalytic activity is affected. Assaying catalytic activity of purified 
PDE4D in vitro after addition of recombinant integrin D5 tails revealed no changes. PDE4D5 
activity is also regulated by phosphorylation; one important site is S651, which can be 
phosphorylated by Erk and suppresses enzymatic activity 45. Western blotting with an antibody 
to this site showed that S651 phosphorylation increased in cells on collagen compared to FN, 
independent of fluid shear stress. Further, the reduced phosphorylation on FN was lost in the 4E 
mutant (Fig. 6a). Cells expressing the chimeric integrin D5/2 plated on FN also showed high 
S651 PDE4D phosphorylation compared to WT D5 cells (Fig. 6b). These data suggest either 
that the integrin D5-PDE4D interaction suppresses S651 phosphorylation or that integrin D2 
activates it. Analysis of cells expressing wild type or 4E mutant PDE4D5 were analyzed in 
suspension or after adhesion to FN-coated dishes. Plating on FN triggered S651 
dephosphorylation in wild type PDE4D5 but not the 4E mutant (Fig. 6c). Chimeric integrin D5/2 
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also failed to trigger S651 dephosphorylation on FN (Fig. 6c). Thus, binding to integrin D5 in 
cells on FN induces PDE4D5 S651 dephosphorylation.  
Proteomic analysis revealed PP2A in PDE4D5 immunoprecipitates in ECs on FN (Fig. S3a). 
Co-immunoprecipitation confirmed this interaction in cells on FN but not matrigel (Fig. S3b). 
Both the PP2A inhibitor okadaic acid (OA) and siRNA against the PP2A catalytic subunit 
blocked FN-dependent S651 dephosphorylation after plating on FN (Fig. S3c) and in stable 
monolayers (Fig. S3d, e) without affecting endothelial cell adhesion, spreading or FAK activation 
on FN (Fig. S4a, b). However, these treatments efficiently blocked NF-NB activation by flow and 
IL1E on FN (Fig. S3f, g).      
We next addressed whether S651 phosphorylation controls ECM-specific NFNB activation. For 
ECs on collagen, expression of phospho-resistant S651A mutant in PDE4D knock-down cells 
increased NF-NB activity (Fig. 6d). Conversely, in cells on FN, rescue of PDE4D5 knock down 
with phospho-mimetic S651E mutant failed to restore NFNB activation (Fig. 6e). These results 
show that control of PDE4D5 phosphorylation on S651 by integrins determines subsequent 
inflammatory signaling.   
Endothelial specific knock-down of PDE4D inhibits inflammation 
We next investigated whether PDE4D is required for flow-dependent inflammatory activation of 
the endothelium in vivo using siRNA. For these experiments, we used recently developed nano-
particles that are highly specific to ECs and do not knock-down genes in hematopoietic cells, 
including leukocytes, or in hepatocytes, even at a high dose (2.0 mg/kg)46. We first screened 
multiple siRNAs and identified a sequence that depleted mouse PDE4D in vitro with an IC50 of 
0.05 nM (Fig. S5a), which is ~100x lower than most siRNAs. Transfection into cultured mouse 
ECs abolished flow-dependent NF-NB activation and ICAM-1 induction, which was rescued by 
viral expression of human PDE4D5 (Fig. 7a), thus, confirming the efficacy and specificity of this 
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siRNA sequence. A version of this siRNA was chemically modified to improve stability and 
packaged into nanoparticles, then injected intravenously into mice (1.0 mg/kg). Isolation of 
aortic endothelial mRNA 14 days after injection showed a ~70% decrease in PDE4D mRNA 
compared to the luciferase control siRNA (Fig. S5b). C57BL6 mice were then injected three 
times in a month with PDE4D or luciferase siRNA nanoparticles. The PDE4D siRNA greatly 
reduced inflammatory gene expression in an atheroprone artery segment compared to 
luciferase siRNA (Fig. 7b).  
Effects on atherosclerosis 
Lastly, we investigated atherosclerosis in the integrin D5/2 chimeric mice by breeding onto the 
hypercholesterolemic ApoE-/- background, which, on a high fat, “Western” diet, develop 
atherosclerotic plaques at regions of disturbed flow, similar to human disease 47.  Aortas from 
these mice after 4 months on a high fat diet showed dramatically decreased plaque burden (Fig 
7c).  These results validate the connection between early inflammatory activation of the 
endothelium by disturbed shear and later disease progression in hyperlipidemia.  
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Discussion 
Inflammation has frequently been described as a double edged sword that is required for tissue 
defense, remodeling and repair but, if not properly regulated, causes damage or disease 48, 49.  
Inflammatory reactions therefore need to be initiated upon infection, injury or stress, but then 
resolved when the infection is cured, injury healed or stress relieved.  Linking the biochemical 
and structural changes associated with tissue repair and remodeling with the pathways that 
govern inflammation appears to be essential for proper regulation of these processes 50, 51.  
Vascular remodeling to adapt to changes in tissue demand requires inflammatory activation of 
the endothelium and recruitment of leukocytes, mainly monocytes, which aid in remodeling 6, 7.  
These processes also involve degradation of basement membranes and synthesis of a 
provisional, fibronectin-rich ECM.  Once morphogenesis is completed, new basement 
membrane synthesis is a key part of the resolution phase for formation of stable, quiescent 
vessels 52, 53.  Atherosclerosis may be considered a form of pathological flow-dependent 
remodeling where ECs in regions of disturbed flow undergo inflammatory activation but can 
never adapt to restore quiescence 54.  WT mice show chronic inflammatory activation of the 
endothelium in regions of disturbed flow 55 which, when other risk factors are present, 
progresses to atherosclerosis. FN deposition beneath the endothelium is an early event in this 
process, appearing first in the regions of low grade inflammation in WT mice and increasing in 
atherosclerosis 13.  FN in the endothelial layer is also abundant in lesions from human arteries 56.  
Moreover, several genetic manipulations that reduce FN in the vessel wall reduce 
atherosclerosis in mice 14-16, as does an antagonist of integrin D5E1 24.  Interestingly, while 
classic genetic studies that searched for single genes that affect artery disease identified mainly 
lipid metabolism and inflammatory genes, a recent analysis of gene networks identified ECM 
and ECM remodeling gene networks as equivalently important 57.  Thus, genetic analysis 
support a role for tight integration of inflammatory and ECM pathways in vascular remodeling. 
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Previous work showed that in cells on collagen or basement membrane, flow-induced activation 
of the cAMP/PKA pathway inhibits inflammatory activation of the endothelium 22. Recent work 
has also identified PKA-independent anti-inflammatory actions of cAMP on inflammasome 
assembly58-60. The provisional FN-rich ECM relieves this inhibition and allows inflammatory 
activation.  Our data show that these effects are mediated through direct binding of PDE4D5 to 
the integrin D5 tail. This interaction localizes PDE4D5 to focal adhesions, induces its proximity 
to PP2A, with subsequent dephosphorylation on an inhibitory site. This dephosphorylation 
increases enzymatic activity to decrease cAMP levels and increase endothelial inflammatory 
activation. These effects were observed both in vitro and in vivo, the latter in mice where the 
integrin D5 cytoplasmic domain was replaced with that of D2, and after knockdown of PDE4D5.  
S651 of PDE4D5 is potentially phosphorylated by Erk2 45. However, in cells on collagen or 
basement membrane, S651 phosphorylation was high in both high and low serum, and was 
unaffected by the MEK inhibitor U0126 despite large changes in Erk activity, and was adhesion-
independent. Instead, PDE4D5 S561 phosphorylation was controlled by matrix-specific, PP2A-
dependent dephosphorylation. Thus, plating cells on FN or shear stress-dependent integrin 
activation results in recruitment of PDE4D5 into focal adhesions and dephosphorylation of S651.  
A number of anti-inflammation drugs are in development or clinical trial for treatment of 
atherosclerosis 61. Interestingly, both genetic deletion of plasma FN and an integrin D5E1 
antagonist reduced atherosclerotic plaque in mouse models 16 23. However, FN contributes to 
hemostasis, fibrosis and other essential functions, thus, its systemic inhibition is unlikely to be 
clinically viable 62, 63. The integrin D5-PDE4D interaction may therefore provide a more specific 
target to inhibit plaque progression without globally affecting FN function.  It should also bypass 
adverse effects of PDE4 catalytic inhibitors 35. Further studies will be required to understand 
how the molecular events and interactions defined here play out during the complex physiology 
14 
 
and pathology of vessel remodeling, atherosclerosis and other instances of chronic 
inflammation. 
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Methods  
 
Cell culture 
BAECs were grown in DMEM containing 10% FBS and penicillin/streptomycin. HUVECs were 
grown in DMEM/F12, 10% FBS, 5 mg/ml ECGS, 100 Pg/ml heparin, penicillin/streptomycin or 
EGM media (Lonza). Mouse endothelial cells were grown in DMEM containing 20% FBS, 1X 
non essential amino acids (Gibco), 2 mM L-glutamate, 50 Pg/ml gentamycin, 4 Pg/ml 
amphotericine B, 100 Pg/ml heparin, 5 mg/ml ECGS and penicillin/streptomycin. Primary mouse 
endothelial cells were isolated from the lung, using rat anti-mouse CD31 antibody (clone 
MEC13.3, Pharmingen, #553370) and Dynabeads (cat. no. 110.35, Invitrogen) as previously 
described 64. No cell lines were used in this study. 
 
Generation of BAECs expressing the integrin D5/2 chimera 
BAECs were infected with retrovirus containing human wild type integrin D5 or the D5/2 chimera. 
Infected cells were selected with puromycin (0.5 Pg/ml) and FACS-sorted for high expressors 
with mAb16 which recognizes human specific integrin D5 extracellular domain. Similar surface 
expression of wild type and integrin chimera was achieved by sorting.  
 
Generation of iMAECs expressing NFNB reporter 
iMAECs were first infected with lenti-virus containing human PDE4D5-GFP and sorted for the 
cells with similar level of expression to endogenous PDE4D5. The cells were then infected with 
lenti-virus for NFNB-reporter65, which induces expression of GFP upon NFNB activation.  
 
Plasmids and siRNA 
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Human integirn D5 wild type and integrin D5/2 chimera were cloned into pLPCX (Clontech) 
using NotI and ClaI sites. D2 tail sequence was fused to D5 sequence in frame by PCR using 
primers containing D2 tail sequences. siRNA resistant PDE-4D5 wild type and mutants were first 
cloned into pBOB-GFP vector using  XbaI and AgeI sites. Then PDE4D5-GFP fragments were 
PCR amplified using the primers, 5’-gcaagcttatggctcagcagacaagcccgg-3’ and 5’-
gaattcttacttgtacagctcgtccatgc-3’, then subcloned into pLPCX vector using HindIII and EcoRI 
sites. For introducing silent mutations into human PDE4D5, the sequence 5’-
atacaaactctgagttggccttgatgta-3’ was used. PDE4D siRNA sequence used in cultured cells  was 
5’-AAGAACUUGCCUUGAUGUACA-3’ from 66. The siRNA for in vivo knock-down of PDE4D 
was 5’-GAACGAGAUUUGUUAAAAAdTdT-3’, and the siRNA for in vivo knock-down of 
Luciferase was 5’-CUUACGCUGAGUACUUCGAdTdT-3’ 46. siRNAs used in vivo were modified 
to prevent immunostimulation, as previously described 46, 67. PDE4D5 F2, F3 and F4 fragments 
cloned into pGEX-4T1 were previously described 66. The other PDE4D5 fragments were PCR-
amplified and cloned into pGEX-4T1 vector between EcoRI and XhoI sites. For deletion 
fragment analysis used in figure 5E, the following amino acid sequences of PDE4D5 were fused 
to GST; '1:123-284, '2: 123-272, '3: 123-260, '4: 123-248. Two siRNA sequences for bovine 
PP2A-CDare 5’-CCAUGACCGAAAUGUAGUAdTdT-3’ and 5’-
GCAUGACUGUAGAUAAGAAdTdT-3’. FAT-PDE4D5-GFP was constructed by inserting FAT 
domain (cloned from HUVEC cDNA) into N-terminus of pLPCX-PDE4D5-GFP construct using 
Gibson assembly.  
 
Animals 
The Integrin D5/2 chimera C57BL/6 strain was generated using homologous recombination by 
OZgene (Austrailia). Floxed-Neo mice were crossed with CMV-Cre line (stock number 006054) 
to create the chimera knock-in mice. For atherosclerosis analysis, integrin chimera knock-in 
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mice were bred with ApoE null mice (stock number 002052).  All animal experiments were 
performed under protocols approved by Yale University Institutional Animal Care and Use. No 
statistical method was used to predetermine sample size. The animal experiments were not 
randomized. The investigators were not blinded to allocation during experiments and outcome 
assessment. 
 
Shear stress experiments 
Serum-starved endothelial cells were replated on glass slides coated with the indicated proteins 
for 5 hr before flow application. The slides were loaded into parallel plate flow chambers. 
Pulsatile laminar shear of 15 ± 5 dynes/cm2 was used to mimic flow profile in athero-resistant 
regions of artery. Oscillatory shear of 1 ± 5 dynes/cm2, 1 Hz was used to mimic disturbed flow in 
athero-prone regions.   
 
Measurement of prostacyclin production 
To measure the stable prostacyclin metabolite 6-keto-PGF1D, HUVECs were starved overnight 
in 1% medium containing 1% FBS, then were plated on glass slides coated with FN or matrigel 
for 5 hr to form a confluent monolayer. Cells were then treated with pulsatile laminar shear (15 ± 
5 dynes/cm2) for 90 min or left untreated. The medium was centrifuged to remove detached 
cells and 6-keto-PGF1D assayed using the ELISA kit (Enzo life sciences) according to the 
manufacturer’s instructions. 
 
In vivo PDE4D knock-down 
PDE4D siRNA or control luciferase siRNA were packaged into endothelial-specific nanoparticles 
and injected at 1 mg/kg via tail vein into WT (C57Bl6) mice. After two weeks, mouse aortas 
were isolated and intimal RNA was prepared as described 68. Briefly, mice were euthanized 
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according to Yale Universty IACUC protocol. Aortas were isolated and flushed with 250 PL 
QIAzol lysis reagent by insulin syringe to elute endothelial RNA, which was purified by 
miRNeasy mini kit (Qiagen) and amplified using a whole transcriptome amplification kit (Qiagen) 
according to the manufacturer’s instructions. PDE4D transcript levels were measured by qRT-
PCR using amplified diluted cDNA template. After confirming the dose and time course for in 
vivo PDE4D knockdown, WT (C57Bl6) mice were injected with PDE4D or control siRNA, once a 
week for 3 weeks. Aortas were harvested at the end of fourth week and stained for inflammatory 
markers. 4 male mice (3 month old) were used for each condition.  
Immunohistochemistry 
Mice were euthanized according to the Yale University IACUC protocol and perfused via the left 
ventricle with 4% paraformaldehyde (PFA). Aortas along with carotid branches were dissected 
and fixed overnight in PFA. For cryosections, tissue was embedded in OCT and frozen on dry 
ice. Longitudinal cryosections (10-ȝm) were prepared with the cryostat. For immunostaining, 
cryosections were fixed in -20 °C acetone for 10 minutes. Sections were blocked in IHC Tek 
antibody diluent for 1 hour at RT. Primary antibodies at the indicated concentrations in IHC-Tek 
antibody diluent and incubated overnight at 4°C. After washing 3 times in PBS, sections were 
incubated with Alexa Flour 598-conjugated Donkey anti rabbit/rat secondary antibody (1:200, 
Invitrogen) for 1 hour at RT. After washing with PBS, sections were mounted in Vectashield with 
DAPI (Vector Laboratories) and images taken using a confocal microscope. 4 male mice (3 
month old) were used for each condition to monitor inflammatory markers on inner curvature of 
aortic arch. For atherosclerosis analysis, the integrin chimera mice in ApoE null background (4 
male mice with age of three months) were on high fat diet for 4 months. Aortas were opened 
and stained en face with Sudan IV. 
  
Antibodies 
D-p-NFNB p65 (S536): rabbit mAb (93H1), Cell Signaling (3033L), 1/1,000 for immnoblotting. 
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D-p-Creb (S133): rabbit mAb (87G3), Cell Signaling (9198S), 1/1,000 for immunoblotting. 
D-PKAc: mouse mAb, BD Transduction Laboratories (610981), 1/1,000 for immunoblotting. 
D-integrin D2: rabbit polyclonal, Millipore (AB1936), 1/1,000 for immunoblotting. 
D-VCAM-1: rabbit mAb (EPR5047), Abcam (ab134047), 1/200 for immunohistochemistry. 
D-ICAM-1: rat mAb (YN1/1.7.4.), BioLegend (116101), 1/200 for immunohistochemistry. 
D-ICAM-1: rabbit polyclonal, Abcam (ab124759), 1/1,000 for immunoblotting. 
D-NFkB-p65: rabbit polyclonal (C-20), Santa Cruz (sc-372), 1/2,000 for immunoblotting. 
D-Vinculin: mouse mAb (VIN-11-5), Sigma (V4505), 1/500 for immunohistochemistry. 
D-fibronectin: rabbit polyclonal, Sigma (F3648), 1/400 for immunohistochemistry. 
D-p-FAK (Tyr397): rabbit polyclonal, Cell Signaling (3283S), 1/1,000 for immunoblotting. 
D-FAK: rabbit polyclonal, Cell Signaling (3285S), 1/1,000 for immunoblotting. 
D-PP2A, C subunit: mouse mAb (1D6), Millipore (05-421), 1/1,000 for immunoblotting. 
Band intensities from immunoblotting were quantified by densitometry using imageJ software.  
 
PKA activity assay 
Active PKA was isolated by pull downs with GST-PKI and quantified as described 69. In brief, 
bacterially expressed GST-PKI was immobilized on GSH-agarose beads. Cell lysates were 
prepared in lysis buffer containing 25 mM Tris-HCl, pH 7.4, 0.5 mM EDTA, 0.5 mM EGTA, 10 
mM E-mercaptoethanol, protease inhibitor cocktail and 1 mM PMSF. After brief sonication and 
centrifugation, the supernatants were added with 100 PM ATP and 1 mM MgCl2, then incubated 
with the GST-PKI beads for 20 min at 4 °C and washed three times with wash buffer (50 mM 
Tris, pH7.4, 100 PM ATP and 1 mM MgCl2). Bound active PKA was eluted with sample buffer 
and immunoblotted with anti-PKA catalytic subunit antibody (BD).  
 
Immunoprecipitation 
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Cells were lysed in 20 mM PIPES pH 6.8, 1% TX-100, 150 mM NaCl, 150 mM sucrose, 0.2% 
sodium deoxycholate, 500 PM EDTA and protease inhibitors. After incubation on ice for 15 min 
and centrifugation, supernatants were diluted 10X in buffer containing 20 mM PIPES pH 6.8, 1% 
TX-100, 150 mM NaCl, 150 mM sucrose, 2.5 mM MgCl2 and 2.5 mM MnCl2. Ab-conjugated 
protein A beads were incubated with the lysates for 2 hr at 4 °C before washing with dilution 
buffer. 
  
Proteomic analysis for PDE4D5 binding proteins 
FLAG-tagged PDE4D5 was stably expressed in BAECs using retroviral infection. The cells were 
plated on FN for 30 min and lysed for immunoprecipitaion with FLAG antibody. FLAG peptides 
were used to elute from immune complexes from control non-infected cells and PDE4D5 
expressing cells. After SDS PAGE and silver staining, specific bands were excised and 
submitted to Yale Keck Biotechnology Resource Laboratory for LC-MS/MS analysis.  
 
In vitro binding assays 
For the binding assay using integrin tails on beads, 30 Pg of integrin D tail proteins were 
incubated with 6 Pl of cobalt beads (Clontech). Washed beads were incubated with 100 ng of 
purified PDE4D5 fragment for 1 hr in buffer containing 20 mM PIPES pH 6.8, 1% TX-100, 150 
mM NaCl, 150 mM sucrose. For GST-pull down analysis for PDE4D domain mapping, 5 Pg of 
GST fusion proteins on GSH-agarose beads were incubated with 100 ng of purified integrin D5 
tail proteins in buffer containing 20 mM PIPES pH 6.8, 1% TX-100, 150 mM NaCl, 150 mM 
sucrose and 1 mg/ml BSA for 1 hr at 4 °C, then washed and analyzed by SDS-PAGE and 
Western blotting.  
 
Cell adhesion and spreading assay 
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Cells were detached and replated on dishes coated with either poly-L-lysine or FN (10 Pg/ml) for 
15 min.  Adherent cells were quantified using the acid phosphatase assay 70 and normalized to 
the cells attached on PLL-coated dishes for 1 hr. To assess cell spreading, cells plated for the 
indicated times were fixed and stained with Alexa Fluor 488-conjugated wheat germ agglutinin 
(invitrogen, 5 Pg/ml), imaged with spinning disk confocal microscopy (Nikon) and cell areas 
were quantified using imageJ software. 
 
Fibronectin fibrillogenesis assay 
WT or a5/2 cells were plated on FN-coated coverslips and grown until they form monolayers. 
Cells were incubated with 1 % FBS containing media for three days, fixed and then stained with 
D-FN antibody (Sigma).  
 
Statistics and Reproducibility 
Statistics were analyzed using Student’s t-test or 1-way ANOVA (multiple comparisons) in 
GraphPad Prism 6. Statistical significance was taken as p<0.05. Data are represented as 
means ± SEM. Pull-down and co-immunoprecipitation results were confirmed in 3 independent 
experiments. 
 
Data availability 
 
Statistics Source Data are available in Supplementary Table 1. All other data are available from  
the authors on reasonable request. 
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Figure legends 
Figure 1. Integrin D subunit cytoplasmic tails determine ECM-specific inflammatory 
signaling.  
(a) Alignment of integrin D subunit tail sequences and schematic representation of integrin D5/2 
chimera. (b, c) NFNB activation by flow. Wild type D5 or D5/2 cells on fibronectin (20 Pg/ml) 
were subjected to 30 min laminar shear (b) or 18h oscillatory shear (c). NFNB activation was 
then assayed by Western blotting for S536 p65 phosphorylation (b; n=3, c; n=4). LS; Laminar 
shear, OS; Oscillatory shear. (d) Induction of ICAM-1 after 18 hr of oscillatory flow in cells 
expressing WT D5 vs. the D5/2 chimera on fibronectin (n=3). (e-g) NFNB activation by soluble 
atherogenic factors.  Wild type BAECs on FN or diluted matrigel were stimulated with IL-1E or 
oxidized LDL for 30 min. NF-NB was assayed by Western blotting for pS536 p65 (e). 
Quantification in f (n=7) and g (n=4) shows activation relative to control cells on FN without flow. 
(h) Effect of the chimera on PKA activation. Wild type D5 or D5/2 chimera cells on FN were 
sheared for 15 min and active PKA was pulled down from cell lysates with GST-PKI followed by 
immunoblotting. Forskolin (FSK) was used as a positive control for PKA activation (n=4-8). (i) 
PKA inhibition rescues NFNB activation in D5/2 chimera cells. Chimera cells on FN were treated 
with the PKI 14-22 amide inhibitor or DMSO only, then subjected to oscillatory shear for 18 hr. 
Activation of NFNB was assayed by Western blotting (n=4). Data are represented as means ± 
SEM. *p<0.05 by one way ANOVA (b, c, h, i) or two-tailed t-test (d, f, g). In all panels n values 
represent independent experiments. Source data are provided in Supplementary Table 1. 
Unprocessed scans of blots are shown in Supplementary Figure 6. 
 
Figure 2. Integrin chimera knock-in mouse showed reduced inflammation in artery 
(a) Targeting strategy. These floxed, knock in mice were then bred with CMV-Cre TG mice to 
obtain germline replacement of the exon containing the integrin D5 cytoplasmic domain with the 
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integrin D2 cytoplasmic domain. (b) A genomic DNA fragment from homozygous knock in mice 
containing the integrin D5 tail was PCR-amplified and sequenced. (c) Validation of integrin 
chimera knock-in mouse. Lung homogenates from wild type and chimera knock-in mice were 
Western blotted with the indicated antibodies.  (d, e) Endothelial cells isolated from adult wild 
type or chimera knock-in homozygous mice were replated on dishes coated with poly-L-lysine or 
FN (10 Pg/ml).  (d) After 15 min, adherent cells were quantified using the acid phosphatase 
assay and normalized to the cells attached on PLL (n=3 independent experiments). Error bars 
are SEM. (e) Cell spreading at the indicated times was determined as described in Methods. 
For each condition, n=20 images (~10 cells/field) pooled across three independent experiments. 
The box plot shows the median, with upper and lower percentiles, and the bars show maxima 
and minima values. Source data for d are available in Supplementary Table 1. (f) Inflammatory 
markers in an athero-prone artery segment of knock-in mice. Aortas from wild type and chimera 
knock-in homozygous mice were stained for the indicated proteins and the lesser curvature of 
the arch was examined. Staining intensity was quantified as described in Methods (n=5 mice for 
each type). L; Lumen. Data are represented as means ± SEM. *p<0.05 by two-tailed t-test. 
Scale bar: 35 Pm. Quantification data from individual mice are provided in Supplementary Table 
1. 
 
Figure 3. Prostacyclin mediates shear-dependent PKA activation but is ECM-independent 
(a) HUVECs on matrigel were pretreated with aspirin (ASA, COX inhibitor, 10 PM) or 
prostacyclin receptor antagonist (RO1138452, 100 nM) then sheared for 15 min. PKA activity 
was measured as in Fig. 1 (n=3). LS; Laminar shear, OS: Oscillatory shear. (b, c) HUVECs on 
matrigel pretreated with aspirin (10 PM) or RO1138452 (100 nM) were exposed to oscillatory 
shear for 18 hr, then NFNB S536 phosphorylation measured by Western blotting. (b; n=4, c; 
n=3). (d) D5/2 chimera expressing BAECs on FN were treated with indometacin (10 PM) or 
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RO1138452 (100 nM), then sheared for 15 min. PKA activity was measured as in a (n=3). (e, f) 
D5/2 chimera cells on FN pretreated with indometacin (10 PM) or RO1138452 (100 nM), were 
exposed to oscillatory shear for 18 hr. NFNB activation was measured as in b and c (n=5). (g) 
HUVECs on matrigel or FN were subjected to pulsatile shear (15 dynes/cm2±5 dynes/cm
2
) for 
90 min.  6-keto-PGFD in the medium was measured by ELISA (n=4). Data are represented as 
means ± SEM. *p<0.05 by one way ANOVA (b, c, e, f) or two-tailed t-test (a, d, g). In all panels 
n values represent independent experiments. Source data are provided in Supplementary Table 
1.  
 
Figure 4. Involvement of PDE4D in ECM-dependent inflammatory signaling  
(a) BAECs on FN were treated with the PDE4 inhibitor rolipram (1 PM), sheared, and PKA 
activity assayed as in Fig 1.  (n=5). (b) BAECs on FN or collagen were treated with rolipram (1 
PM) and assayed for NFNB as before (n=3). (c) HUVEC lysates were immunoprecipitated with 
two different PDE4D5 antibodies and Western blots probed for integrin D5 or integrin D2. Similar 
results were obtained in 3 experiments. (d) BAECs expressing wild type integrin D5 or the D5/2 
chimera were immunoprecipitated with human-specific integrin D5 antibody recognizing the 
extracellular region. Western blots were probed for PDE4D5 and for the integrin E1 subunit. 
Similar results were obtained in 4 experiments. (e) BAECs were transfected with siRNA against 
PDE4D and then rescued with control or PDE4D5-GFP retrovirus. Cells were subjected to 
oscillatory shear and NFNB assayed as before. (n=4). (f) BAECs expressing wild type PDE4D5 
or FAT-PDE4D5 were plated on matrigel for 5hr and subjected to oscillatory shear. NFNB S536 
phosphorylation and Creb S133 phosphorylation were measured by Western blotting (n=4). 
Data are represented as means ± SEM. *p<0.05 by one way ANOVA (a, e, f) or two-tailed t-test 
(b). In all panels n values represent independent experiments. Source data are provided in 
Supplementary Table 1. Unprocessed scans of blots are shown in Supplementary Figure 6. 
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Figure 5. Mapping the integrin binding site on PDE4D5.   
(a) Schematic representation of PDE4D5 and fragments used for pull-down assays. 
(b) HUVEC lysates were incubated with GST-tagged fragments of PDE4D5 and probed for 
integrin D5. Results are representative of 3 independent experiments. (c) To test whether the 
interaction is direct, integrin D tails immobilized on cobalt beads were incubated with purified 
PDE4D5-F2 fragment. Beads were washed and bound material was analyzed by western 
blotting. (D5R = scrambled sequence of D5 tail.) (d) Deletion constructs used for detailed 
mapping and critical residues for binding. (e, f) The indicated PDE4D5 fragments and mutants 
were immobilized on GSH beads and incubated with D5 tail protein used in c. Bound D5 tail 
protein was detected by Western blotting with integrin D5 antibody against cytoplasmic tail. 
Results are representative of 3 independent experiments. (g) BAECs expressing GFP-tagged 
PDE4D5 wild type or 4E mutant were plated on fibronectin or collagen and sheared for 15 min.  
The cells were fixed and stained for the focal adhesion marker, vinculin. Results are 
representative of 3 independent experiments. Scale bar: 50 Pm.  (h) BAECs stably expressing 
integrin D5 binding-deficient PDE4D5 mutants (4A and 4E) or catalytically inactive mutant 
(D556A) were transfected with siRNA to knock down the endogenous PDE4D, then were 
subjected to oscillatory shear for 18 hr. NFNB activity was assayed as in Fig. 1; (n=3 
independent experiments). Data are represented as means ± SEM. *p<0.05 by two-tailed t-test. 
Source data are provided in Supplementary Table 1. Unprocessed scans of blots are shown in 
Supplementary Figure 6. 
 
Figure 6. ECM-dependent regulation of PDE4D phosphorylation  
(a) BAECs expressing wild type or 4E mutant of PDE4D5 were plated on collagen or FN for 5 hr 
then sheared for 15 min. Cell lysates were probed for anti-pS651-PDE4D (n=4-6). (b) BAECs 
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expressing WT integrin D5 or the D5/2 chimera on fibronectin, transfected with PDE4D5, then 
sheared for 15 min. S651 phosphorylation was assayed by Western blotting as in a (n=3). (c) 
BAECs expressing PDE4D5 wild type or the 4E mutant or chimera cells expressing PDE4D5 
wild type were kept in suspension for 90 min then replated on FN-coated dishes for the 
indicated times. S651 phosphorylation was assayed by Western blotting (n=3). (d, e) BAECs in 
which endogenous PDE4D5 was knocked down were reconstituted with WT, phospho-deficient 
S651A or phospho-mimetic S651E mutants. The cells were replated on collagen (d) (n=3) or FN 
(e) (n=6) then subject to oscillatory shear for 2 hrs. NFNB activity was assayed as in Fig 1. In all 
panels n values represent independent experiments. Data are represented as means ± SEM. 
*p<0.05 by one way ANOVA (a, b, d) or two-tailed t-test (c, e). Source data are provided in 
Supplementary Table 1. Unprocessed scans of blots are shown in Supplementary Figure 6. 
 
Figure 7. In vivo PDE4D knock-down reduces flow-dependent inflammation  
(a) Validation of siRNA used for in vivo knock-down. Immortalized mouse aortic endothelial cells 
(iMAEC) were expressed with GFP-tagged human PDE4D5 and transfected with siRNA used 
for nanoparticle formulation.  NFNB activation was assayed either by measuring GFP-reporter 
expression under control of NFNB responsive element or ICAM-1 induction. Data are 
represented as means ± SEM. *p<0.05 and #p=0.079 by two-tailed t-test. (n=3 independent 
experiments) Source data are provided in Supplementary Table 1. (b) Nano-particles containing 
PDE4D siRNA or luciferase siRNA (1 mg/kg) were injected intravenously. Aortas from treated 
mice were isolated and stained for the indicated molecules to assay inflammatory markers in 
lesser curvature (n=5 mice). Scale bar: 35 Pm. (c) Integrin chimera knock-in mice were bred 
with ApoE null mice and fed with high fat diet for 4 months. Aortas were opened and stained en 
face with Sudan IV (n=4 mice). Plaque area and numbers were quantified. Data are represented 
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as means ± SEM. *p<0.05 by two-tailed t-test. Quantification data from individual mice are 
provided in Supplementary Table 1.  
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Supplementary Figure 1. Characterization of D5/2 chimera endothelial cells 
(a) BAECs expressing human integrin wild type D5 or the D5/2 chimera were stained with 
mAb16 that recognizes human integrin D5 extracellular domain. (b) Wild type D5 or the D5/2 
chimera cells were lysed and immunoprecipitated with mAb16 to isolate exogenous human 
integrin D proteins. Western blots with antibodies against the D5 and D2 cytoplasmic tails 
confirm the sequences (upper and middle panels), and show similar pairing with the E1 subunit 
(lower panel). (c, d) Wild type D5 and D5/2 chimera cells spreading on fibronectin. BAECs 
expressing wild type integrin D5 or the chimera were detached and replated on dishes coated 
with fibronectin (10 Pg/ml) for the indicated times. The cells were either fixed and stained with 
wheat germ agglutinin (c) or lysed and subjected to immunoblotting for FAK phosphorylation 
(Y397) (d). (e) Wild type D5 or D5/2 chimera cells were plated on fibronectin and grown to 
monolayer and then kept in low-serum media (1% FBS) for two days to induce fibronectin 
fibrillogenesis.  The cells were fixed and stained for fibronectin. For each condition, n=30 
images pooled across three independent experiments were averaged. The box plot shows the 
median, with upper and lower percentiles, and the bars show maxima and minima values. (f) 
Wild type D5 or D5/2 chimera cells were plated on fibronectin and sheared for 36 hrs 
(20dynes/cm2). Cells were stained with phalloidin and Hoechst and alignment in the direction of 
flow was quantified (±30°). Scale bars: 50 Pm. n=10 images (60-100 cells/field) were used for 
quantification for each condition. Error bars are SEM. 
 
Supplementary Figure 2. PDE4D5 is responsible for ECM-dependent inflammation in 
endothelial cells.  
(a) BAECs on FN or collagen were treated with rolipram (1 PM) and assayed for AMPK 
activation. (b) Immunoblotting HUVEC lysate with pan PDE4D antibody detects the major band 
co-migrating with reference PDE4D5 (left panel). The band was diminished by transfection with 
PDE4D siRNA, demonstrating specificity. Similarly, PDE4D5 was the only isoform detectable in 
BAEC lysate with immunobotting using pan PDE4D antibody or PDE4D5 specific antibody (right 
two panels). * indicates non-specific bands. (c) BAECs expressing wild type PDE4D5 or FAT-
PDE4D5 were plated on MG for 1hr to monitor GFP signal. 
 
Supplementary Figure 3. PP2A regulates PDE4D5 phosphorylation and inflammation  
(a) Identification of PP2A as a PDE4D5 binding protein. FLAG-PDE4D5 expressing BAECs on 
FN were lysed and immunoprecipitated with FLAG antibody. Bound protein with size of 35 kDa 
was submitted for mass analysis and identified as PP2A catalytic subunit. (b) BAECs 
expressing FLAG-tagged PDE4D5 were plated on either FN or matrigel for indicated times. 
PDE4D5 was immunoprecipitated with FLAG antibody and eluted with FLAG peptides. Similar 
results were obtained in 3 experiments. (c) BAECs expressing PDE4D5 wild type were kept in 
suspension for 90 min then replated on FN-coated dishes for the indicated times. For okadaic 
acid treatment, cells in suspension were added with 5 nM OA for last 20 min before replating on 
FN. S651 phosphorylation was assayed by Western blotting (n=4 independent experiments). (d) 
BAECs expressing PDE4D5 were plated on FN for 5 hr then pretreated with DMSO or okadaic 
acid (OA, 5 nM) and then stimulated with IL1E for 30 min. S651 phosphorylation was assayed 
by Western blotting (n=3 independent experiments). (e) BAECs expressing PDE4D5 were 
transfected with a siRNAs targeting PP2A catalytic subunit. The cells were replated on FN then 
subject to laminar shear for 30 min. (f) BAECs were plated on FN for 5 hr then pretreated with 
DMSO or okadaic acid (OA, 5 nM) and then stimulated with IL1E for 30 min. NFNB activity was 
assayed by Western blotting (n=3 independent experiments). (g) BAECs were transfected with 
two different siRNAs targeting the PP2A catalytic subunit. The cells were replated on FN then 
subject to oscillatory shear for 2 hrs (n=3 independent experiments). Data are represented as 
means ± SEM. *p<0.05 by one way ANOVA (d, g) or two-tailed t-test (c, f). Source data are 
provided in Supplementary Table 1. 
 
Supplementary Figure 4. Effect of PP2A inhibition on endothelial cell adhesion 
(a) BAECs were transfected with PP2A siRNA or treated with okadaic acid (OA, 5 nM, 1hr) and 
plated on FN (10 Pg/ml) for 1hr. Cell adhesion was quantified as described in Supplementary 
Fig. 2 (n=3 independent experiments) and cell morphology was examined after fixation and 
phalloidin and nuclear staining. Error bars are SEM. Scale bar: 100 Pm. (b) BAECs treated as (a) 
were plated on FN (10 Pg/ml) for indicated times and FAK phosphorylation was measured by 
Western blotting.  
 
Supplementary Figure 5. In vivo knock-down of endothelial PDE4D  
(a) NIH3T3 cells were transfected with either luciferase siRNA or mouse PDE4D siRNA used for 
in vivo knock-down.  After 72h, PDE4D5 was assayed by Western blotting with tubulin as a 
loading control. (b) Nano-particles containing PDE4D siRNA or luciferase siRNA (1 mg/kg) were 
injected intravenously. After two weeks, mouse aortas were isolated, and endothelial expression 
of PDE4D was assayed by qPCR (n=4). (c) Serum lipid profile of D5/2; ApoE(-/-)  mice after 
high fat diet (n=6 mice). Data are represented as means ± SEM. *p<0.05 by two-tailed t-test. 
Source data are provided in Supplementary Table 1. 
 
 
 
Supplementary Figure 6. Unprocessed scans of key blots  
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